| Literature DB >> 35035910 |
Taeok Kim1, Shakti Chandra Mondal1, Chae-Rim Jeong1, So-Rim Kim1, O-Hyun Ban2, Young Hoon Jung3, Jungwoo Yang2, Soo-Jung Kim1.
Abstract
For applications of microorganisms as probiotics in the food industry, safety evaluation has increasingly become important to ensure the health of consumers. Although people have been using various lactic acid bacteria for different purposes, some studies have reported that certain lactic acid bacteria exhibit properties of virulence and produce toxic compounds. Thus, it is necessary to examine the characteristics associated with lactic acid bacteria that are safe for use as probiotics. This research aimed to assess the safety of Lactococcus lactis IDCC 2301 isolated from homemade cheese using in vitro and in vivo assays, including antibiotic resistance, hemolytic activity, toxin production, infectivity, and metabolic activity in immune-compromised animal species. The results demonstrated that the strain was susceptible to nine antibiotics suggested by the European Food Safety Authority (EFSA). Whole-genome analysis revealed that L. lactis IDCC 2301 neither has toxigenic genes nor harbors antibiotic resistance. Moreover, L. lactis IDCC 2301 showed neither hemolytic nor β-glucuronidase activity. Furthermore, none of the D-lactate and biogenic amines were produced by L. lactis IDCC 2301. Finally, it was demonstrated that there was no toxicity and mortality using single-dose oral toxicity tests in rats. These results indicate that L. lactis IDCC 2301 can be safely used as probiotics for human consumption.Entities:
Keywords: Lactococcus lactis IDCC2301; homemade cheese; probiotics; safety evaluation
Year: 2021 PMID: 35035910 PMCID: PMC8751446 DOI: 10.1002/fsn3.2648
Source DB: PubMed Journal: Food Sci Nutr ISSN: 2048-7177 Impact factor: 2.863
Carbohydrate utilization by Lactococcus lactis IDCC2301
| No. | Substrate | Result | No. | Substrate | Result | No. | Substrate | Result | No. | Substrate | Result |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Glycerol | − | 14 | L‐Sorbose | − | 27 | Cellobiose | + | 40 | D‐Turanose | − |
| 2 | Erythritol | − | 15 | Rhamnose | − | 28 | Maltose | + | 41 | D‐Lyxose | − |
| 3 | D‐Arabinose | − | 16 | Dulcitol | − | 29 | Lactose | − | 42 | D‐Tagatose | − |
| 4 | L‐Arabinose | − | 17 | Inositol | − | 30 | Melibiose | − | 43 | D‐Fucose | − |
| 5 | Ribose | + | 18 | Mannitol | − | 31 | Sucrose | + | 44 | L‐Fucose | − |
| 6 | D‐Xylose | − | 19 | Sorbitol | − | 32 | Trehalose | + | 45 | D‐Arabitol | − |
| 7 | L‐Xylose | − | 20 | α‐Methyl‐D‐mannoside | − | 33 | Inulin | − | 46 | L‐Arabitol | − |
| 8 | Adonitol | − | 21 | α‐Methyl‐D‐glucoside | − | 34 | Melezitose | − | 47 | Gluconate | − |
| 9 | β‐Methyl‐xylose | − | 22 | N‐Acetyl‐glucosamine | + | 35 | D‐Raffinose | − | 48 | 2‐keto‐gluconate | − |
| 10 | Galactose | + | 23 | Amygdaline | +w | 36 | Amidon | +w | 49 | 5‐keto‐gluconate | − |
| 11 | D‐Glucose | + | 24 | Arbutine | − | 37 | Glycogene | − | |||
| 12 | D‐Fructose | + | 25 | Esculin | + | 38 | Xylitol | − | |||
| 13 | D‐Mannose | + | 26 | Salicin | +w | 39 | Gentibiose | + |
(+), utilization; (+W), weak utilization; (−) non‐utilization.
Minimum inhibitory concentration (MIC) of Lactococcus lactis IDCC 2301 against nine antibiotics
| AMP | CLI | CHL | ERY | GEN | KAN | STR | TET | VAN | |
|---|---|---|---|---|---|---|---|---|---|
| Cutoff value | 2 | 1 | 8 | 1 | 32 | 64 | 32 | 4 | 4 |
|
| 0.25/S2 | 0.125/S | 4/S | <0.125/S | 8/S | 16/S | 16/S | 0.25/S | 1/S |
Abbreviations: AMP, ampicillin; CLI, clindamycin; CHL, chloramphenicol; ERY, erythromycin; GEN, gentamicin; KAN, kanamycin; S, Susceptible; STR, streptomycin; TET, tetracycline; VAN, vancomycin.
EFSA (European Food Safety Authority) (EFSA & FEEDAP, 2012).
FIGURE 1Genomic map of Lactococcus lactis IDCC 2301. Marked features are seen from outside to the center; CDS on the forward strand, CDS on the reverse strand, tRNA, rRNA, GC content, and GC skew
Hemolytic activities of L. lactis IDCC 2301. S. aureus ATCC 25923 and Lactobacillus reuteri IDCC3701 were used as the positive and negative controls, respectively, for β‐hemolysis
| Scheme | After test | |
|---|---|---|
|
|
| |
| Region | Strains | Note |
| T sample |
| – |
| β control |
| Transparent ring by the hemolytic phenomenon |
| γ control |
| No phenomenon |
Enzymatic activities of L. lactis IDCC2301
| Enzyme | Activity |
|---|---|
| Alkaline phosphate | − |
| Esterase | − |
| Esterase lipase | − |
| Lipase | − |
| Leucine arylamidase | + |
| Valine arylamidase | − |
| Cysteine arylamidase | − |
| Trypsin | − |
| α‐Chymotrypsin | + |
| Acid phosphatase | + |
| Naphthol‐AS‐BI‐phosphohydrolase | + |
| α‐Galactosidase | − |
| β‐Galactosidase | − |
| β‐Glucuronidase | − |
| α‐Glucosidase | − |
| β‐Glucosidase | + |
| N‐Acetyl‐β‐glucosaminidase | − |
| α‐Mannosidase | − |
| α‐Fucosidase | − |
The ratio of l‐ to d‐lactate produced by L. lactis IDCC2301
| Strain |
(mg/mL) |
(mg/mL) | Ratio (%) | |
|---|---|---|---|---|
| L‐form | D‐form | |||
|
| 18.27 ± 0.40 | N.D. | 100 | 0 |
Abbreviation: N.D., not detected
Body weight changes in the tested rats
| Dose (mg/kg B. W. | Group | Day(s) after administration | ||||
|---|---|---|---|---|---|---|
| 0 | 1 | 3 | 7 | 14 | ||
| Ll | 9‐week‐old | 215.2 ± 4.7 | 236.4 ± 9.1 | 243.9 ± 5.7 | 256.5 ± 9.5 | 260.5 ± 7.0 |
| 10‐week‐old | 229.4 ± 1.0 | 253.2 ± 2.2 | 255.8 ± 3.3 | 264.0 ± 2.7 | 267.7 ± 4.8 | |
| Ll, 2000 | 9‐week‐old | 216.5 ± 15.1 | 237.4 ± 20.7 | 242.1 ± 17.5 | 254.1 ± 22.4 | 264.8 ± 24.5 |
| 10‐week‐old | 231.6 ± 11.6 | 250.0 ± 11.5 | 257.9 ± 9.3 | 273.3 ± 9.3 | 280.4 ± 13.7 | |
Abbreviation: BW, body weight.
Ll, Lactococcus lactis IDCC 2301.